Abstract
EZH2 is an oncogene in non-Hodgkin lymphoma. Understanding the underlying pathogenic mechanisms will be essential to improve treatments for patients with EZH2 mutant lymphomas. Recently Donaldson-Collier and colleagues (Nat. Genet. 2019; published online January 28, https://doi.org/10.1038/s41588-018-0338-y) examined the effects of mutant EZH2 on the 3D architecture of the lymphoma genome, highlighting the potential relevance of chromatin folding dynamics.
Original language | English |
---|---|
Pages (from-to) | 362-365 |
Number of pages | 4 |
Journal | Trends in Molecular Medicine |
Volume | 25 |
Issue number | 5 |
DOIs | |
Publication status | Published - May 2019 |
Keywords / Materials (for Non-textual outputs)
- Chromatin/genetics
- Enhancer of Zeste Homolog 2 Protein/genetics
- Genetic Predisposition to Disease
- Genome-Wide Association Study
- Genomics/methods
- Humans
- Lymphoma, Non-Hodgkin/genetics
- Mutation